Business
Successful Completion of Sixth Dose Escalation
Successful Completion of Sixth Dose Escalation.
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n\n \n \n \n\n\nThis announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended (\"MAR\"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n19 September 2023\n \nAvacta Group plc\n \n(\"Avacta\" or the \"Company\" and, together with its subsidiary undertakings, the \"Group\")\n \nSuccessful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update\n \n- Excellent safety profile of AVA6000 continues to be observed in the sixth dose escalation cohort.\n- Significant reduction in tumour volume confirmed in a patient with soft tissue sarcoma.\n- Cohort 7 to be the final dose escalation cohort in the Phase 1a three weekly dosing study.\n- Revised regulatory strategy aims to achieve earlier commencement of pivotal Phase 2 study in soft tissue sarcoma in 2024.\n- Detailed Phase 1a data expected to be released in Q4 2023.\n \nAvacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces the successful completion of the sixth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 and provides an update on clinical progress.\n \nThe data from the sixth cohort continue to show an excellent safety profile for AVA6000. Additionally, a tumour response (significant tumour volume reduction) has been confirmed in a patient with soft tissue sarcoma on the trial, and there are further indications of clinical activity in patients across other indications.\n \nAVA6000 is a tumour targeted form of doxorubicin that has been chemically modified with Avacta's pre|CISION™ platform, designed to reduce systemic side effects by targeting the release of the active chemotherapy to tumour tissue.\n \nA total of 35 patients with a range of advanced and/or metastatic solid tumours have now been dosed at the clinical trial in sites in t...